PharmaSGP Holding SE · ISIN: DE000A2P4LJ5 · EQS - Company News

PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised 

PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised  Gräfelfing, November 14, 2024 – In the third quarter of 2024, the German OTC pharmaceutical company PharmaSGP Holding SE was able to continue the dynamic business development of the first half of the year, generating revenues of €88.6 million in the first nine months of 2024 based on preliminary, unaudited figures. This represents an increase of 17.0% over the same period of the previous year (€75.7 millio...

XETR:PSG Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News PharmaSGP Holding SE

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (2)
Short Selling (DE) (0)
Short Selling (UK) (0)
14 November 2024 07:30AM
PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised 
DE000A2P4LJ5
PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised  Gräfelfing, November 14, 2024 – In the third quarter of 2024, the German OTC pharmaceutical company PharmaSGP Holding SE was able to continue the dynamic business development of the first half of the year, generating revenues of €88.6 million in the first nin...
PharmaSGP Holding SE
About the publication
05 November 2024 10:07AM
Peter Gerckens succeeds Natalie Weigand as of January 1, 2025
DE000A2P4LJ5
CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025   Gräfelfing, November 05, 2024 - German OTC pharmaceutical company PharmaSGP Holding SE is announcing a change in the position of Chief Executive Officer (CEO). After more than seven years as CEO, Natalie Weigand informed the Supervisory Board today...
PharmaSGP Holding SE
About the publication
05 November 2024 10:02AM
Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer
DE000A2P4LJ5
PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer Gräfelfing, November 05, 2024 – Peter Gerckens, who has been a member of the Management Board of PharmaSGP Holding SE as Chief Commercial Officer (CCO) since July 1, 2024, will take over the position of Chief Executive Officer (CEO) of the company on January ...
PharmaSGP Holding SE
About the publication
01 October 2024 08:15AM
PharmaSGP Holding SE has purchased 477,701 own shares through its public share repurchase offer
DE000A2P4LJ5
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.   PharmaSGP Holding SE has purchased 477,701 own sha...
PharmaSGP Holding SE
About the publication
12 September 2024 08:15AM
PharmaSGP continues dynamic growth path in the first half of 2024
DE000A2P4LJ5
PharmaSGP continues dynamic growth path in the first half of 2024 Gräfelfing, September 12, 2024 – The German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic growth path in the first half of 2024, achieving half-year revenues of €58.4 million based on preliminary, unaudited figures. This represents an increase of 17.4% compa...
PharmaSGP Holding SE
About the publication
12 September 2024 08:10AM
PharmaSGP Holding SE resolves on public share repurchase offer to buy back own shares for up to 594,405 shares
DE000A2P4LJ5
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE AD-HOC RELEASE. Disclosure of an inside information acc. to Art. 17...
PharmaSGP Holding SE
About the publication
27 June 2024 09:45AM
Annual General Meeting approves full distribution of the Group’s profit for 2023 following a successful business performance
DE000A2P4LJ5
PharmaSGP Holding SE: Annual General Meeting approves full distribution of the Group’s profit for 2023 following a successful business performance 89.74% of the share capital was represented; all agenda items were approved Shareholders approve increased dividend distribution of €1.36 per dividend-bearing share The appointment of Peter Gerckens ...
PharmaSGP Holding SE
About the publication
21 June 2024 07:30AM
PharmaSGP Holding SE strengthens the Management Board to further accelerate growth
DE000A2P4LJ5
PharmaSGP Holding SE strengthens the Management Board to further accelerate growth PharmaSGP expands the Management Board as of July 1, 2024 with Peter Gerckens as Chief Commercial Officer (CCO), a newly created position Peter Gerckens will be responsible for international markets, sales and new businesses Gräfelfing, June 21, 2024 – German OTC p...
PharmaSGP Holding SE
About the publication
14 May 2024 07:30AM
PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024
DE000A2P4LJ5
PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024 Gräfelfing, May 14, 2024 – German OTC pharmaceutical company PharmaSGP Holding SE continued the positive business development of 2023 in the first quarter of 2024 and achieved an increase in revenues of 25.6% to €30.1 million (prior-year quarter: €24.0 mil...
PharmaSGP Holding SE
About the publication
18 April 2024 08:31PM
PharmaSGP Holding SE proposes an increased dividend of EUR 1.36 per share for 2023
DE000A2P4LJ5
Publication of inside information in accordance with Article 17 of Regulation (EU) No 596/2014   PharmaSGP Holding SE proposes an increased dividend of EUR 1.36 per share for 2023 Gräfelfing, April 18, 2024 – The Management Board and Supervisory Board of PharmaSGP Holding SE (ISIN DE000A2P4LJ5) will propose to this year's Annual General Meeting ...
PharmaSGP Holding SE
About the publication
16 April 2024 07:30AM
PharmaSGP exceeds the € 100 million revenues mark in 2023 and plans further profitable growth in 2024
DE000A2P4LJ5
PharmaSGP exceeds the € 100 million revenues mark in 2023 and plans further profitable growth in 2024 Gräfelfing, April 16, 2024 – German OTC pharmaceutical company PharmaSGP Holding SE continued the successful development of previous years in the 2023 financial year and exceeded the € 100 million revenues mark for the first time in the company's ...
PharmaSGP Holding SE
About the publication
14 November 2023 07:30AM
PharmaSGP continues the profitable growth course of the previous quarters in the third quarter of 2023
DE000A2P4LJ5
PharmaSGP continues the profitable growth course of the previous quarters in the third quarter of 2023 Gräfelfing, November 14, 2023 – German OTC pharmaceutical company PharmaSGP Holding SE continued the positive business development of the previous quarters in the third quarter of 2023. Based on preliminary, unaudited figures, quarterly revenues ...
PharmaSGP Holding SE
About the publication
14 September 2023 07:30AM
PharmaSGP achieves top performance in the first half of 2023
DE000A2P4LJ5
PharmaSGP achieves top performance in the first half of 2023 Gräfelfing, September 14, 2023 – In the first half of 2023, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic performance of the previous quarters, achieving half-year revenues of € 49.7 million based on preliminary, unaudited results. This corresponds to an i...
PharmaSGP Holding SE
About the publication
29 June 2023 07:30AM
Strong support at 2023 AGM for very successful business development
DE000A2P4LJ5
PharmaSGP Holding SE: Strong support at 2023 AGM for very successful business development 91.11% of share capital represented; all agenda items approved Shareholders approve dividend distribution of EUR 0.49 per dividend-bearing share In 2022, PharmaSGP had again achieved record revenues with significant increase in profitability After strong y...
PharmaSGP Holding SE
About the publication
29 June 2023 07:30AM
PharmaSGP Holding SE: Strong support at 2023 AGM for very successful business development
DE000A2P4LJ5
PharmaSGP Holding SE: Strong support at 2023 AGM for very successful business development 91.11% of share capital represented; all agenda items approved Shareholders approve dividend distribution of EUR 0.49 per dividend-bearing share In 2022, PharmaSGP had again achieved record revenues with significant increase in profitability After strong y...
PharmaSGP Holding SE
About the publication
10 May 2023 07:30AM
PharmaSGP with a significant leap in revenue in Q1 2023 – EBITDA grows by more than 40%
DE000A2P4LJ5
PharmaSGP with a significant leap in revenue in Q1 2023 – EBITDA grows by more than 40% Gräfelfing, 10 May 2023 – In the first quarter of 2023, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic performance of the previous quarters and achieved the highest level of quarterly revenue in the company’s history to date at € 2...
PharmaSGP Holding SE
About the publication
10 May 2023 07:30AM
PharmaSGP with a significant leap in revenue in Q1 2023 – EBITDA grows by more than 40%
DE000A2P4LJ5
PharmaSGP with a significant leap in revenue in Q1 2023 – EBITDA grows by more than 40% Gräfelfing, 10 May 2023 – In the first quarter of 2023, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic performance of the previous quarters and achieved the highest level of quarterly revenue in the company’s history to date at € 2...
PharmaSGP Holding SE
About the publication
19 April 2023 07:30AM
PharmaSGP plans dividend distribution of 49.2% after record year in 2022
DE000A2P4LJ5
PharmaSGP plans dividend distribution of 49.2% after record year in 2022   Gräfelfing, 19 April 2023 – The German OTC pharmaceutical company, PharmaSGP Holding SE (WKN A2P4LJ), remains on track for highly profitable growth. The Munich-based company posted the best set of figures in its history in financial year 2022, generating revenue of € 85.8...
PharmaSGP Holding SE
About the publication
19 April 2023 07:30AM
PharmaSGP plans dividend distribution of 49.2% after record year in 2022
DE000A2P4LJ5
PharmaSGP plans dividend distribution of 49.2% after record year in 2022   Gräfelfing, 19 April 2023 – The German OTC pharmaceutical company, PharmaSGP Holding SE (WKN A2P4LJ), remains on track for highly profitable growth. The Munich-based company posted the best set of figures in its history in financial year 2022, generating revenue of € 85.8...
PharmaSGP Holding SE
About the publication
15 March 2023 07:30AM
PharmaSGP confirms record revenue and record profitability for 2022 and publishes forecast for 2023
DE000A2P4LJ5
  PharmaSGP confirms record revenue and record profitability for 2022 and publishes forecast for 2023   Gräfelfing, 15 March 2023 – Based on preliminary and unaudited figures German OTC pharmaceutical company PharmaSGP Holding SE has achieved a significant increase of 31.3% in revenue resulting in a new record of € 85.8 million in financial year...
PharmaSGP Holding SE
About the publication
15 March 2023 07:30AM
PharmaSGP confirms record revenue and record profitability for 2022 and publishes forecast for 2023
DE000A2P4LJ5
  PharmaSGP confirms record revenue and record profitability for 2022 and publishes forecast for 2023   Gräfelfing, 15 March 2023 – Based on preliminary and unaudited figures German OTC pharmaceutical company PharmaSGP Holding SE has achieved a significant increase of 31.3% in revenue resulting in a new record of € 85.8 million in financial year...
PharmaSGP Holding SE
About the publication
14 March 2023 06:17PM
PharmaSGP Holding SE releases forecast for full year 2023
DE000A2P4LJ5
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014   PharmaSGP Holding SE releases forecast for full year 2023   Gräfelfing, March 14, 2023 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has agreed on the forecast for consolidated revenue and adjusted consolidated earnings before intere...
PharmaSGP Holding SE
About the publication
14 March 2023 06:17PM
PharmaSGP Holding SE releases forecast for full year 2023
DE000A2P4LJ5
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014   PharmaSGP Holding SE releases forecast for full year 2023   Gräfelfing, March 14, 2023 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has agreed on the forecast for consolidated revenue and adjusted consolidated earnings before intere...
PharmaSGP Holding SE
About the publication
20 February 2023 07:30AM
PharmaSGP achieves new record revenue of more than € 85.5 million for 2022 exceeding analysts’ expectations
DE000A2P4LJ5
PharmaSGP achieves new record revenue of more than € 85.5 million for 2022 exceeding analysts’ expectations   Gräfelfing, 20 February 2023 – Based on preliminary, unaudited figures the German OTC pharmaceuticals company PharmaSGP has achieved revenues of between € 85.5 and € 86 million for financial year 2022. Thus, the Munich-based company reac...
PharmaSGP Holding SE
About the publication
20 February 2023 07:30AM
PharmaSGP achieves new record revenue of more than € 85.5 million for 2022 exceeding analysts’ expectations
DE000A2P4LJ5
PharmaSGP achieves new record revenue of more than € 85.5 million for 2022 exceeding analysts’ expectations   Gräfelfing, 20 February 2023 – Based on preliminary, unaudited figures the German OTC pharmaceuticals company PharmaSGP has achieved revenues of between € 85.5 and € 86 million for financial year 2022. Thus, the Munich-based company reac...
PharmaSGP Holding SE
About the publication
03 January 2023 04:13PM
PharmaSGP Holding SE resolves on buyback program for own shares of up to 1.5 million Euro
DE000A2P4LJ5
PharmaSGP Holding SE resolves on buyback program for own shares of up to 1.5 million Euro Gräfelfing, Germany, January 3, 2023 - The Management Board of PharmaSGP Holding SE (ISIN DE000A2P4LJ5, „PharmaSGP“) has decided today, with the approval of the Supervisory Board, utilizing the authorization of the General Meeting of May 28, 2020, to buy-back ...
PharmaSGP Holding SE
About the publication
16 November 2022 07:30AM
PharmaSGP posts record revenues (+39%) and record earnings (+54%) in 9M 2022 – raises full-year forecast
DE000A2P4LJ5
PharmaSGP posts record revenues (+39%) and record earnings (+54%) in 9M 2022 – raises full-year forecast   Gräfelfing, 16 November 2022 – German OTC pharmaceutical company PharmaSGP Holding SE has once again in the third quarter continued to experience the dynamic development seen in previous periods. Provisional unaudited figures show the compan...
PharmaSGP Holding SE
About the publication
16 November 2022 07:30AM
PharmaSGP posts record revenues (+39%) and record earnings (+54%) in 9M 2022 – raises full-year forecast
DE000A2P4LJ5
PharmaSGP posts record revenues (+39%) and record earnings (+54%) in 9M 2022 – raises full-year forecast   Gräfelfing, 16 November 2022 – German OTC pharmaceutical company PharmaSGP Holding SE has once again in the third quarter continued to experience the dynamic development seen in previous periods. Provisional unaudited figures show the compan...
PharmaSGP Holding SE
About the publication
10 November 2022 04:59PM
PharmaSGP Holding SE raises forecast for FY 2022
DE000A2P4LJ5
PharmaSGP Holding SE raises forecast for FY 2022 Gräfelfing, November 10, 2022 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has decided today, based on an evaluation of actual business data completed today, to raise the forecast for group revenue and adjusted group earnings before interest, taxes, depreciation and amortizati...
PharmaSGP Holding SE
About the publication
10 November 2022 04:59PM
PharmaSGP Holding SE raises forecast for FY 2022
DE000A2P4LJ5
PharmaSGP Holding SE raises forecast for FY 2022 Gräfelfing, November 10, 2022 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has decided today, based on an evaluation of actual business data completed today, to raise the forecast for group revenue and adjusted group earnings before interest, taxes, depreciation and amortizati...
PharmaSGP Holding SE
About the publication
01 September 2022 07:30AM
PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022
DE000A2P4LJ5
PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022   Gräfelfing, 1 September 2022 – In the first half of 2022, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic performance of the previous quarters, achieving half-year revenues of € 42.0 million based on preliminary, unaudited...
PharmaSGP Holding SE
About the publication
01 September 2022 07:30AM
PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022
DE000A2P4LJ5
PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022   Gräfelfing, 1 September 2022 – In the first half of 2022, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic performance of the previous quarters, achieving half-year revenues of € 42.0 million based on preliminary, unaudited...
PharmaSGP Holding SE
About the publication
21 July 2022 07:29AM
PharmaSGP successfully secures financing of up to € 160 million
DE000A2P4LJ5
PharmaSGP successfully secures financing of up to € 160 million   Gräfelfing, 21 July 2022 – Following strong organic growth and the successful acquisition and integration of the four OTC brands Baldriparan®, Formigran®, Spalt® and Kamol® formerly owned by the GlaxoSmithKline Group (GSK) in the second half of 2021, PharmaSGP Holding SE achieved r...
PharmaSGP Holding SE
About the publication
21 July 2022 07:29AM
PharmaSGP successfully secures financing of up to € 160 million
DE000A2P4LJ5
PharmaSGP successfully secures financing of up to € 160 million   Gräfelfing, 21 July 2022 – Following strong organic growth and the successful acquisition and integration of the four OTC brands Baldriparan®, Formigran®, Spalt® and Kamol® formerly owned by the GlaxoSmithKline Group (GSK) in the second half of 2021, PharmaSGP Holding SE achieved r...
PharmaSGP Holding SE
About the publication
15 June 2022 04:59PM
PharmaSGP Holding SE successfully holds 2022 AGM
DE000A2P4LJ5
PharmaSGP Holding SE successfully holds 2022 AGM - 91.07% of share capital represented - Shareholders approve proposed dividend payment; all other agenda items approved by a clear majority - Following record revenue in 2021, Management Board reports on growth prospects based on PharmaSGP platform Gräfelfing, 15 June 2022 – PharmaSGP Holding SE ...
PharmaSGP Holding SE
About the publication
17 May 2022 07:30AM
PharmaSGP: Another revenue record – Q1 2022 revenues up 67% year-on-year
DE000A2P4LJ5
PharmaSGP: Another revenue record – Q1 2022 revenues up 67% year-on-year   Gräfelfing, 17 May 2022 – In the first quarter of 2022, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic growth path of the previous quarters and achieved another revenue record of € 20.6 million on the basis of preliminary, unaudited results. ...
PharmaSGP Holding SE
About the publication
25 April 2022 07:30AM
PharmaSGP expects to see clear double-digit revenue and profit growth in 2022
DE000A2P4LJ5
PharmaSGP expects to see clear double-digit revenue and profit growth in 2022   Gräfelfing, 25 April 2022 - After another record year, German pharmaceutical company PharmaSGP is targeting revenues of between 78 and 82 million euro for financial year 2022, up from 65.3 million euro in the year before, equating to planned growth of at least 19.5%....
PharmaSGP Holding SE
About the publication
04 April 2022 07:30AM
PharmaSGP - Dividend at the upper end of the announced bandwidth after a record year in 2021
DE000A2P4LJ5
PharmaSGP - Dividend at the upper end of the announced bandwidth after a record year in 2021   Gräfelfing, 04 April 2022 - At the end of February German OTC pharmaceuticals company PharmaSGP Holding SE (WKN: A2P4LJ) announced that the company had recorded a revenue record of € 65.3 million in financial year 2021 and adjusted earnings before inter...
PharmaSGP Holding SE
About the publication
15 March 2022 07:30AM
PharmaSGP achieves record results in 2021 - Adjusted EBITDA in Q4 up fivefold year-on-year
DE000A2P4LJ5
PharmaSGP achieves record results in 2021 - Adjusted EBITDA in Q4 up fivefold year-on-year   Gräfelfing, 15 March 2022 - Based on preliminary and as yet unaudited results, German OTC pharmaceutical company PharmaSGP Holding SE achieved revenues of € 65.3 million in 2021, representing a record in the company's history. The adjusted earnings before...
PharmaSGP Holding SE
About the publication
17 February 2022 07:30AM
PharmaSGP achieves record revenues in 2021 and exceeds analysts' expectations
DE000A2P4LJ5
PharmaSGP achieves record revenues in 2021 and exceeds analysts' expectations Gräfelfing, 17 February 2022 - German OTC pharmaceutical company PharmaSGP achieved revenues of around € 65 million in the financial year 2021, reaching the upper end of the published guidance (€ 60 million to € 65 million). With the highest revenue in its company histor...
PharmaSGP Holding SE
About the publication
16 November 2021 07:30AM
PharmaSGP reporting 34% revenue growth and increased profitability in Q3 2021
DE000A2P4LJ5
PharmaSGP reporting 34% revenue growth and increased profitability in Q3 2021 Recorded at € 19.7 million, group revenue in Q3 2021 is around 34% above the previous year and around 40% above Q2 2021, both representing significant increases Strong revenue development largely driven by organic growth in the existing portfolio Integration of the acqu...
PharmaSGP Holding SE
About the publication
16 September 2021 07:30AM
PharmaSGP: Product portfolio further expanded and internationalisation driven forward in H1 2021
DE000A2P4LJ5
PharmaSGP: Product portfolio further expanded and internationalisation driven forward in H1 2021 Group revenues (€ 26.4 million) and adjusted EBITDA (€ 6.5 million) impacted by an overall market burdened by Covid-19 Visible improvement in Q2 despite continued difficult market environment; market recovery expected in H2 Acquisition of Baldriparan(...
PharmaSGP Holding SE
About the publication
15 September 2021 06:58PM
PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio
DE000A2P4LJ5
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014 PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio Gräfelfing, September 15, 2021 - Following the scheduled closing on August 31, 2021 of the agreement signed with the GlaxoSmithKline Group on the acqui...
PharmaSGP Holding SE
About the publication
31 August 2021 05:43PM
PharmaSGP Group completes acquisition of OTC brand portfolio (Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R)) from GSK
DE000A2P4LJ5
PharmaSGP Group completes acquisition of OTC brand portfolio (Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R)) from GSK Gräfelfing, August 31, 2021 - PharmaSGP Holding SE announces the formal completion of the purchase agreement signed mid of June with GlaxoSmithKline Group on the acquisition of an OTC portfolio comprising the brands Baldripar...
PharmaSGP Holding SE
About the publication
25 June 2021 11:38AM
PharmaSGP successfully holds first AGM after IPO
DE000A2P4LJ5
PharmaSGP successfully holds first AGM after IPO   2021 Ordinary AGM held virtually due to the pandemic 87.3 % of the share capital was represented All agenda items approved with clear majorities Management Board reports on growth prospects based on PharmaSGP platform Gräfelfing, 25 June 2021 - PharmaSGP Holding SE has successfully held its 2...
PharmaSGP Holding SE
About the publication
15 June 2021 06:02PM
PharmaSGP Group acquires OTC brand portfolio (Baldriparan, Formigran, Spalt  and Kamol) from GSK
DE000A2P4LJ5
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014 At the same time publication pursuant to § 111c of the German Stock Corporation Act (Aktiengesetz)   PharmaSGP Group acquires OTC brand portfolio (Baldriparan, Formigran, Spalt and Kamol) from GSK Gräfelfing, June 15, 2021 - PharmaSGP GmbH, a subsidiary of P...
PharmaSGP Holding SE
About the publication
18 May 2021 07:30AM
PharmaSGP: Expected business development in Q1 2021
DE000A2P4LJ5
PharmaSGP: Expected business development in Q1 2021 Group revenues of € 12.4 million and adjusted EBIT of € 2.0 million impacted by an overall market still significantly burdened by Covid-19 Focus category "Health Brands" and category "Beauty Brands" report revenue developments in line with expectations Market environment in Q2 remains difficul...
PharmaSGP Holding SE
About the publication
31 March 2021 07:30AM
PharmaSGP: Revenue growth in 2020 despite declining markets
DE000A2P4LJ5
PharmaSGP: Revenue growth in 2020 despite declining markets At €63.2 million, group revenue showed slight growth in a market environment severely impacted by Covid-19 Growth drivers: strategically important 'Health Brands' category grew revenue by 11.8%, International markets showed strong growth with 18.6% Adjusted EBIT with €16.5 million below...
PharmaSGP Holding SE
About the publication
More PharmaSGP Holding SE related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 2 25th November 2024 FUTRUE GmbH DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN